On Thursday, Freedom Capital Markets initiated coverage on Nutex Health (NASDAQ: NUTX), assigning a Buy rating to the company's shares with a price target set at $56.00. The firm's analysis is based on a positive outlook for the company's unique approach to healthcare through its micro-hospital model.
Nutex Health's strategy involves the deployment of micro-hospitals across the nation, which are designed to offer more accessible, convenient, and cost-effective healthcare services compared to traditional hospitals. These facilities aim to provide a higher level of patient satisfaction with a "concierge" level of care.
Despite facing challenges last year due to changes in reimbursement under the No Surprises Act (NSA), Nutex Health is making a comeback. Freedom Capital Markets sees the current valuation of Nutex Health's shares as an opportunity, suggesting the stock is undervalued.
The $56 price target is based on a multiple of 7 times the firm's FY25 EBITDA estimate of $42 million. The coverage initiation reflects a belief in the company's potential to leverage its innovative healthcare model for growth and recovery from the previous year's setbacks.
Investors are encouraged to consider Nutex Health as a micro-cap investment opportunity in the healthcare sector, with the company's forward-looking model poised for expansion and increased adoption.
In other recent news, Nutex Health has seen a significant third-quarter performance with a 26% increase in revenue and a 974% growth in AEBITDA. Following this, Benchmark raised the stock price target for Nutex Health to $60, up from the previous $45, while maintaining a Buy rating. The Micro Hospital segment, accounting for 91% of the company's revenue, also saw a 26% revenue increase, including a 21% growth in revenue from mature hospitals. Additionally, the company's Population Health segment reported positive income after divesting two unprofitable subsidiaries.
Further, Nutex Health announced plans to open two new micro-hospitals by the end of 2024 and another one in the first quarter of 2025, aligning with a reported 28.0% year-over-year increase in total hospital visits. Also, Maxim Group initiated coverage on the company's stock with a Buy rating and set a price target of $45.00. This outlook is based on Nutex Health's efficient management and expansion of its micro-hospitals, as well as a strong growth trajectory in patient visits.
Lastly, Nutex Health regained compliance with Nasdaq's minimum bid price requirement after a 1:10 reverse stock split. The company's financial position remains stable with $30 million in cash reserves and strong enrollment figures for the Independent (LON:IOG) Physician Associations in Texas and Florida, which are expected to contribute positively to the company's performance.
InvestingPro Insights
Nutex Health's recent performance and financial metrics offer additional context to Freedom Capital Markets' bullish outlook. According to InvestingPro data, the company has shown strong revenue growth, with a 26.02% increase in the last twelve months as of Q3 2024, reaching $292.0 million. This growth trend aligns with the positive view on the company's micro-hospital model expansion.
InvestingPro Tips highlight that Nutex Health has experienced a "Strong return over the last three months" and a "Large price uptick over the last six months," with the stock price showing a remarkable 315.99% total return over the past six months. These trends support the notion that investors are recognizing the company's potential, as suggested by Freedom Capital Markets' analysis.
However, it's important to note that Nutex Health is "Not profitable over the last twelve months," with a negative EPS of -$8.58. Despite this, InvestingPro Tips indicate that "Analysts predict the company will be profitable this year," which could be a key factor in the positive outlook and the assigned Buy rating.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Nutex Health, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.